Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Jun 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5074134012 | Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5074135013 | Chlorzoxazone 500 mg and diclofenac potassium 50 mg and paracetamol 325 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5074136014 | Acetaminophen 325 mg and chlorzoxazone 500 mg and diclofenac potassium 50 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Chlorzoxazone and diclofenac and paracetamol only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Diclofenac potassium | true | Inferred relationship | Some | 1 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Diclofenac potassium | true | Inferred relationship | Some | 1 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Paracetamol | true | Inferred relationship | Some | 2 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Paracetamol | true | Inferred relationship | Some | 2 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Chlorzoxazone | true | Inferred relationship | Some | 3 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Chlorzoxazone | true | Inferred relationship | Some | 3 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 3 | |
| Product containing precisely chlorzoxazone 500 milligram and diclofenac potassium 50 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR